24,285 Bristol Myers Squibb Company $BMY Shares Acquired by Envestnet Portfolio Solutions Inc.

Key Points

• Envestnet Portfolio Solutions increased its Bristol Myers Squibb stake by 28.2%, purchasing 24,285 shares to own 110,400 shares valued at approximately $6.93 million. Institutional investors collectively hold 76.41% of BMY.
• Bristol Myers Squibb exceeded quarterly expectations, reporting $2.04 EPS versus $1.60 expected and $12.97 billion in revenue, up 5.7% year over year. The company also maintained its outlook for fiscal 2026 earnings of $6.75–$7.00 per share.
• The company declared a quarterly dividend of $0.63 per share, equivalent to a 4.1% annualized yield. Analysts rate the stock “Moderate Buy,” with a consensus price target of $67.06 versus its reported opening price of $61.54.

Envestnet Portfolio Solutions Inc. increased its stake in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 28.2% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 110,400 shares of the biopharmaceutical company's stock after buying an additional 24,285 shares during the period. Envestnet Portfolio Solutions Inc.'s holdings in Bristol Myers Squibb were worth $6,930,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Davis Asset Management L.P. bought a new position in Bristol Myers Squibb in the 2nd quarter worth approximately $27,000. Addison Advisors LLC bought a new stake in Bristol Myers Squibb during the 2nd quarter worth about $32,000. Bayban bought a new stake in Bristol Myers Squibb during the 4th quarter worth about $31,000. Groupe la Francaise lifted its position in Bristol Myers Squibb by 562.9% during the 2nd quarter. Groupe la Francaise now owns 590 shares of the biopharmaceutical company's stock valued at $33,000 after purchasing an additional 501 shares during the period. Finally, Kilter Group LLC bought a new position in shares of Bristol Myers Squibb in the 2nd quarter valued at about $35,000. Institutional investors own 76.41% of the company's stock.

Insider Buying and Selling

In other Bristol Myers Squibb news, SVP Phil M. Holzer sold 500 shares of Bristol Myers Squibb stock in a transaction that occurred on Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total value of $33,750.00. Following the transaction, the senior vice president owned 16,862 shares of the company's stock, valued at approximately $1,138,185. The trade was a 2.88% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Company insiders own 0.05% of the company's stock.

Bristol Myers Squibb Stock Up 0.6%

Shares of NYSE:BMY opened at $61.54 on Friday. The company has a 50 day moving average price of $64.44 and a two-hundred day moving average price of $60.15. The company has a debt-to-equity ratio of 1.89, a quick ratio of 1.38 and a current ratio of 1.53. The company has a market capitalization of $125.71 billion, a PE ratio of 13.56, a PEG ratio of 0.30 and a beta of 0.23. Bristol Myers Squibb Company has a 52 week low of $42.52 and a 52 week high of $68.64.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last announced its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.60 by $0.44. The company had revenue of $12.97 billion during the quarter, compared to analyst estimates of $11.74 billion. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. The firm's revenue was up 5.7% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.46 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Analysts forecast that Bristol Myers Squibb Company will post 6.95 earnings per share for the current year.

Bristol Myers Squibb Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, November 2nd. Shareholders of record on Friday, October 2nd will be issued a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 4.1%. The ex-dividend date is Friday, October 2nd. Bristol Myers Squibb's dividend payout ratio (DPR) is 55.51%.

Trending Headlines about Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers Squibb selected Onco360 as a restricted specialty pharmacy for ZENBEXUS (iberdomide), enabling specialty dispensing and clinical support as the newly approved multiple myeloma treatment begins its commercial rollout. The launch could provide a new revenue stream in an underserved patient population. Bristol Myers Squibb Adds Restricted Pharmacy Path for New Myeloma Drug
• Positive Sentiment: Recent traction from newer medicines is helping offset declines from mature products, improving BMY’s revenue mix and supporting the investment case that its growth portfolio can soften upcoming patent losses. Can Recent Traction With Key Drugs and Pipeline Progress Boost BMY?
• Positive Sentiment: Completion of a Phase 1 lung-cancer combination study adds incremental support to Bristol Myers Squibb’s immuno-oncology pipeline, though the early-stage update does not yet establish clinical or commercial success. BMY’s Lung Cancer Combo Study Completion Adds Quiet Support to Its Immuno-Oncology Pipeline
• Positive Sentiment: Zacks added BMY to its Rank #1 Strong Buy list and its Strong Buy income-stock list, potentially improving sentiment among momentum and dividend-focused investors. New Strong Buy Stocks for September 24th
• Neutral Sentiment: Investment coverage highlights BMY’s specialized drug portfolio, strong free cash flow and generous dividend, but also notes the company’s exposure to patent expirations and the need for its pipeline to deliver the next phase of growth. Bristol Myers Squibb vs. Pfizer

Analysts Set New Price Targets

Several brokerages have recently commented on BMY. Argus upgraded shares of Bristol Myers Squibb from a "hold" rating to a "buy" rating and set a $75.00 price target for the company in a research report on Wednesday, August 5th. Wells Fargo & Company set a $65.00 price objective on shares of Bristol Myers Squibb and gave the company an "equal weight" rating in a research note on Friday, July 31st. Guggenheim reaffirmed a "buy" rating and issued a $75.00 price objective (up from $72.00) on shares of Bristol Myers Squibb in a research note on Friday, July 31st. TD Cowen started coverage on shares of Bristol Myers Squibb in a report on Wednesday, August 5th. They set a "buy" rating for the company. Finally, HSBC reiterated a "hold" rating and set a $65.00 target price (up from $60.00) on shares of Bristol Myers Squibb in a research report on Thursday, September 10th. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, ten have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $67.06.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company that discovers, develops and commercializes prescription medicines. Its portfolio includes therapies for cancer, blood disorders, cardiovascular disease, immune-mediated conditions and psychiatric disorders. Key products include Opdivo and Yervoy for oncology, Eliquis for reducing the risk of stroke and systemic embolism, Revlimid for certain blood cancers, and several other specialty medicines.

The company serves patients and healthcare providers in markets around the world, with operations and commercial activities spanning North America, Europe, Asia-Pacific and other international regions.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.